AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16360995 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 80
Study 12610740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally twice daily for 2.5 days
Number of subjects: 9
Study 10622283 — intervention group
Group type: EXPERIMENTAL
Intervention: 3H-paroxetine binding after one year's treatment with different drugs
Number of subjects: 20
Study 10622283 — intervention group
Group type: COMPARATOR
Intervention: 3H-paroxetine binding before treatment
Number of subjects: 20
Study 10622283 — intervention group
Group type: EXPERIMENTAL
Intervention: 3H-paroxetine binding after one year's treatment
Number of subjects: 20
Study 7668493 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluid administration, analgetics, avoidance of oral fluid or food intake in mild acute pancreatitis
Number of subjects: 0
Study 7668493 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis in severe acute pancreatitis
Number of subjects: 0
Study 7668493 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted ventilation and renal dialysis in severe acute pancreatitis
Number of subjects: 0
Study 7668493 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate volume replacement and nutritional support in severe acute pancreatitis
Number of subjects: 0
Study 7668493 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition in pancreatitis treatment
Number of subjects: 0
Study 1719242 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 courses of adjuvant chemotherapy with cis‐platinum, vinblastine and bleomycin
Number of subjects: 225
Study 1719242 — intervention group
Group type: COMPARATOR
Intervention: 4 courses of adjuvant chemotherapy with cis‐platinum, vinblastine and bleomycin
Number of subjects: 225
Study 7005780 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose naproxen (1250 mg/day for 5 days)
Number of subjects: 34
Study 7005780 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naproxen (500 mg loading dose, then 750 mg/day for 5 days)
Number of subjects: 34
Study 7005780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31603732 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) using two diode lasers with doses of 35.71 J/cm2 and 27.77 J/cm2, applied daily in contact and perpendicular to the skin.
Number of subjects: 2
Study 31620980 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 980
Number of subjects: 0
Study 31620980 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab RP
Number of subjects: 0
Study 28939066 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3mg/kg every 2 weeks
Number of subjects: 34
Study 28939066 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice (IC)
Number of subjects: 34
Study 25293644 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive continuum of care intervention
Number of subjects: 0
Study 25293644 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 23460074 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX plus etanercept
Number of subjects: 459
Study 23460074 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (MTX plus sulfasalazine plus hydroxychloroquine)
Number of subjects: 459
Study 23460074 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX monotherapy
Number of subjects: 459
Study 20864245 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking habit
Number of subjects: 3026
Study 20864245 — intervention group
Group type: COMPARATOR
Intervention: Parental smoking habits
Number of subjects: 3026
Study 20864245 — intervention group
Group type: COMPARATOR
Intervention: Number of smokers in the household
Number of subjects: 3026
Study 19092007 — intervention group
Group type: EXPERIMENTAL
Intervention: Buechel‐Pappas (BP) implant
Number of subjects: 200
Study 19092007 — intervention group
Group type: EXPERIMENTAL
Intervention: Scandinavian Total Ankle Replacement (STAR) implant
Number of subjects: 200
Study 19092007 — intervention group
Group type: COMPARATOR
Intervention: Both BP and STAR implants
Number of subjects: 200
Study 17295587 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 mg transdermal nicotine replacement (TNR)
Number of subjects: 134
Study 17295587 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg transdermal nicotine replacement (TNR)
Number of subjects: 134
Study 17295587 — intervention group
Group type: COMPARATOR
Intervention: 0 mg transdermal nicotine replacement (TNR)
Number of subjects: 134
Study 17295587 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 134
Study 17295587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 15023596 — intervention group
Group type: EXPERIMENTAL
Intervention: WELL diet (DASH type diet with weight loss focus)
Number of subjects: 40
Study 15023596 — intervention group
Group type: EXPERIMENTAL
Intervention: WELL diet
Number of subjects: 40
Study 15023596 — intervention group
Group type: COMPARATOR
Intervention: NHF diet
Number of subjects: 40
Study 10759625 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐229 10 mg b.d.
Number of subjects: 24
Study 10759625 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg q.d.s.
Number of subjects: 24
Study 10759625 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐229 5 mg b.d.
Number of subjects: 24
Study 10759625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8724443 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 0
Study 8724443 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.50 mg
Number of subjects: 0
Study 8724443 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.50 mg
Number of subjects: 0
Study 8724443 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 0
Study 8724443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1331484 — intervention group
Group type: EXPERIMENTAL
Intervention: Black patients with KPS of 90 or more
Number of subjects: 1565
Study 1331484 — intervention group
Group type: COMPARATOR
Intervention: White patients with KPS of 90 or more
Number of subjects: 1565
Study 1331484 — intervention group
Group type: EXPERIMENTAL
Intervention: Black patients with KPS of less than 90
Number of subjects: 1565
Study 1331484 — intervention group
Group type: COMPARATOR
Intervention: White patients with KPS of less than 90
Number of subjects: 1565
Study 1331484 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for Blacks and Whites
Number of subjects: 1565
Study 3886563 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 27
Study 3886563 — intervention group
Group type: COMPARATOR
Intervention: propranolol
Number of subjects: 27
Study 29273692 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly-intensive practice (4 hours daily)
Number of subjects: 30
Study 29273692 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately-intensive practice (2 hours daily)
Number of subjects: 30
Study 29273692 — intervention group
Group type: COMPARATOR
Intervention: Waiting period
Number of subjects: 30
Study 27140929 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate hydrochloride (4-week trial including 2-week placebo and 2-week treatment)
Number of subjects: 48
Study 27140929 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2-week period)
Number of subjects: 48
Study 27140929 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (2-week treatment)
Number of subjects: 48
Study 27140929 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessment (1-week typical sleep)
Number of subjects: 48
Study 24705418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry prophylaxis
Number of subjects: 0
Study 24705418 — intervention group
Group type: COMPARATOR
Intervention: TMP-SMX prophylaxis
Number of subjects: 0
Study 22153966 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative lipid management after CABG
Number of subjects: 440
Study 22153966 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients post-operative lipid management after CABG
Number of subjects: 440
Study 20459006 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (operation group)
Number of subjects: 78
Study 20459006 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and splintlet fixation or cast application (non-operation group)
Number of subjects: 78
Study 17921383 — intervention group
Group type: COMPARATOR
Intervention: 25000 IU vitamin A
Number of subjects: 0
Study 17921383 — intervention group
Group type: EXPERIMENTAL
Intervention: 50000 IU vitamin A
Number of subjects: 0
Study 17921383 — intervention group
Group type: EXPERIMENTAL
Intervention: 100000 IU vitamin A
Number of subjects: 0
Study 17921383 — intervention group
Group type: COMPARATOR
Intervention: 0 IU vitamin A
Number of subjects: 0
Study 16251235 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 571
Study 16251235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571
Study 12240782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole granules in orange juice (180 mL)
Number of subjects: 20
Study 12240782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole granules in tomato juice (180 mL)
Number of subjects: 20
Study 12240782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole granules in strained pears (1 tablespoon)
Number of subjects: 20
Study 12240782 — intervention group
Group type: COMPARATOR
Intervention: Intact lansoprazole capsule with water (180 mL)
Number of subjects: 20
Study 10707109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms/kg) with diethylcarbamazine (DEC; 6 mg/kg)
Number of subjects: 51
Study 10707109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (200 micrograms/kg) with albendazole (400 mg)
Number of subjects: 51
Study 10707109 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC (6 mg/kg) with albendazole (400 mg)
Number of subjects: 51
Study 10707109 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg) alone
Number of subjects: 51
Study 8945794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular risk-screening and intervention (one-year program)
Number of subjects: 2984
Study 8945794 — intervention group
Group type: COMPARATOR
Intervention: Control group (not offered intervention)
Number of subjects: 2984
Study 2248082 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide 100 mg single dose
Number of subjects: 17
Study 2248082 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide 200 mg single dose
Number of subjects: 17
Study 2248082 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide 300 mg single dose
Number of subjects: 17
Study 2248082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2248082 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 300 mg 3 times daily for 1 week
Number of subjects: 17
Study 2248082 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 100 mg 3 times daily for 1 week
Number of subjects: 17
Study 2248082 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 200 mg 3 times daily for 1 week
Number of subjects: 17
Study 2248082 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 300 mg 3 times daily for 1 week (24 hours after last dose)
Number of subjects: 17
Study 2248082 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 100 mg 3 times daily in depressed patients
Number of subjects: 17
Study 6446929 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐methyl histamine (H1‐receptor agonist)
Number of subjects: 0
Study 6446929 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0
Study 6446929 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (H1‐receptor antagonist)
Number of subjects: 0
Study 6446929 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐methyl histamine
Number of subjects: 0
Study 6446929 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimaprit (H2‐receptor agonist)
Number of subjects: 0
Study 6446929 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐methyl histamine and either 4‐methyl histamine or dimaprit
Number of subjects: 0
Study 30655038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban administered at 2 hours after thrombolysis (Group A)
Number of subjects: 0
Study 30655038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban administered at 2-12 hours after thrombolysis (Group B)
Number of subjects: 0
Study 30655038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban administered at 12-24 hours after thrombolysis (Group C)
Number of subjects: 0
Study 30655038 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 0
Study 28701162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI diet
Number of subjects: 11
Study 25648155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified HH interventions (S2)
Number of subjects: 125
Study 25648155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified HH interventions plus increased availability of alcohol-based handrub (S3)
Number of subjects: 125
Study 25648155 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care HH education every 3 months (S1)
Number of subjects: 125
Study 25648155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified HH interventions (S2) for HCWs with lower stages of HH commitment
Number of subjects: 125
Study 25648155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified HH interventions plus increased availability of alcohol-based handrub (S3) for HCWs with lower stages of HH commitment
Number of subjects: 125
Study 25648155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified HH interventions plus increased availability of alcohol-based handrub (S3) for HCWs with higher stages of HH commitment
Number of subjects: 125
Study 23963616 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiologic tape
Number of subjects: 40
Study 23963616 — intervention group
Group type: COMPARATOR
Intervention: No kinesiologic tape (control)
Number of subjects: 40
Study 22802250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (120 mg twice daily for 15 days)
Number of subjects: 18
Study 22802250 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir alone (400 mg)
Number of subjects: 18
Study 19239460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5 mg)
Number of subjects: 0
Study 19239460 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg)
Number of subjects: 0
Study 19239460 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dutasteride and tamsulosin
Number of subjects: 0
Study 17601495 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 6 mg
Number of subjects: 444
Study 17601495 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER 12 mg
Number of subjects: 444
Study 17601495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 444
Study 17601495 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg
Number of subjects: 444
Study 15351864 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous unfractionated heparin (continuous infusion of 100 IU/kg/daily)
Number of subjects: 128
Study 15351864 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (50 ml/daily as a continuous infusion)
Number of subjects: 128
Study 15351864 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous unfractionated heparin
Number of subjects: 128
Study 15351864 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 128
Study 11527171 — intervention group
Group type: EXPERIMENTAL
Intervention: Capitonnage (n = 23)
Number of subjects: 42
Study 11527171 — intervention group
Group type: COMPARATOR
Intervention: Open method (n = 19)
Number of subjects: 42
Study 9727959 — intervention group
Group type: EXPERIMENTAL
Intervention: meta-chlorophenylpiperazine (MCPP), 0.35 mg/kg
Number of subjects: 0
Study 9727959 — intervention group
Group type: COMPARATOR
Intervention: meta-chlorophenylpiperazine (MCPP)
Number of subjects: 0
Study 7984968 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b treatment (retreatment once or twice)
Number of subjects: 9
Study 7984968 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b treatment
Number of subjects: 9
Study 2531910 — intervention group
Group type: EXPERIMENTAL
Intervention: mesoglycan (150 mg/die i.m. for five days and 144 mg/die per os for a further twenty‐five days)
Number of subjects: 57
Study 2531910 — intervention group
Group type: COMPARATOR
Intervention: dexamethasone (24 mg/die i.v. for the first ten days)
Number of subjects: 57
Study 392744 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetard (controlled-release acetylsalicylic acid), 1 g X 4 or 2 g X 2 per day
Number of subjects: 24
Study 392744 — intervention group
Group type: COMPARATOR
Intervention: Magnecyl (instant-release acetylsalicylic acid), 1 g X 4 daily
Number of subjects: 24
Study 31519441 — intervention group
Group type: EXPERIMENTAL
Intervention: eCPAP
Number of subjects: 44
Study 31519441 — intervention group
Group type: COMPARATOR
Intervention: dCPAP
Number of subjects: 44
Study 30318492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg per day
Number of subjects: 1077
Study 28241419 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine fortified milk
Number of subjects: 84
Study 28241419 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iodine fortified milk)
Number of subjects: 84
Study 26232570 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management training program (4 training sessions on the nature of epilepsy and self-management)
Number of subjects: 60
Study 26232570 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 23683841 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group CBT (eight, 2‐hour weekly sessions) plus individual dilemma‐focused therapy (eight, 1‐hour weekly sessions)
Number of subjects: 0
Study 23683841 — intervention group
Group type: COMPARATOR
Intervention: CBT alone (eight, 2‐hour group weekly sessions plus eight, 1‐hour individual weekly sessions)
Number of subjects: 0
Study 21819539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin (175 IU kg(‐1) per 24 h) for acute venous thromboembolism
Number of subjects: 87
Study 18321497 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum FSH
Number of subjects: 51
Study 18321497 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum INHB
Number of subjects: 51
Study 18321497 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum AMH
Number of subjects: 51
Study 18321497 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of the larger testis
Number of subjects: 51
Study 18321497 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of INHB and AMH
Number of subjects: 51
Study 18321497 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of FSH, AMH, INHB, or volume of the larger testis
Number of subjects: 51
Study 17298853 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 80 mg/m² plus gemcitabine 1000 mg/m² i.v. on days 1 and 8 with intra-patient alternated dose escalation up to 100 and 1200 mg/m², respectively, over three cycles (arm A)
Number of subjects: 98
Study 17298853 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 80 mg/m² followed by gemcitabine 1000 mg/m² i.v. (100 min) on days 1 and 8 (arm B)
Number of subjects: 98
Study 16544440 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaptanib, injected into the eye every six weeks
Number of subjects: 0
Study 16544440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14559745 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified design in Mwanza trial
Number of subjects: 0
Study 14559745 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified design in Masaka trial
Number of subjects: 0
Study 14559745 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified design in Rakai trial
Number of subjects: 0
Study 14559745 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual matching of communities
Number of subjects: 0
Study 14559745 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmatched study designs with smaller communities
Number of subjects: 0
Study 14559745 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between HIV prevalence and incidence in Mwanza trial
Number of subjects: 0
Study 14559745 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between HIV prevalence and incidence in Masaka trial
Number of subjects: 0
Study 14559745 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between HIV prevalence and incidence in Rakai trial
Number of subjects: 0
Study 11915854 — intervention group
Group type: EXPERIMENTAL
Intervention: Alora 0.1 mg/day
Number of subjects: 321
Study 11915854 — intervention group
Group type: EXPERIMENTAL
Intervention: Alora 0.05 mg/day
Number of subjects: 321
Study 11915854 — intervention group
Group type: COMPARATOR
Intervention: CEE 0.625 mg/day
Number of subjects: 321
Study 11915854 — intervention group
Group type: COMPARATOR
Intervention: CEE 1.25 mg/day
Number of subjects: 321
Study 7718674 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (12.5 mg, i.v.)
Number of subjects: 0
Study 7718674 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers and alcoholics (control group)
Number of subjects: 0
Study 2167788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin infusion at 1 mumol/l
Number of subjects: 4
Study 2167788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin infusion at 2 mumol/l
Number of subjects: 4
Study 2167788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin infusion at 4 mumol/l
Number of subjects: 4
Study 2167788 — intervention group
Group type: COMPARATOR
Intervention: Aspirin infusion at 0 mumol/l (control)
Number of subjects: 4
Study 7232461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (1-6 oz of 95-proof)
Number of subjects: 0
Study 7232461 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital (30-300 mg)
Number of subjects: 0
Study 7232461 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (25-100 mg)
Number of subjects: 0